Immunotherapy Using Gamma Delta T Cells for Cancer
Author Information
Author(s): Nicol A J, Tokuyama H, Mattarollo S R, Hagi T, Suzuki K, Yokokawa K, Nieda M
Primary Institution: University of Queensland
Hypothesis
Can autologous Vγ9Vδ2 T cells combined with zoledronate be safely administered to patients with advanced solid tumors?
Conclusion
The therapy with Vγ9Vδ2 T cells is feasible and well tolerated, but benefits are likely only when combined with other treatments.
Supporting Evidence
- Vγ9Vδ2 T cells showed cytotoxic activity against various tumor cell lines in vitro.
- Patients treated with Vγ9Vδ2 T cells had manageable side effects.
- Three patients experienced disease responses while continuing ineffective therapies.
Takeaway
Doctors are trying to use special immune cells called gamma delta T cells to help fight cancer, and they found it works better when combined with other treatments.
Methodology
The study involved a phase I clinical trial with 18 patients receiving Vγ9Vδ2 T cells and zoledronate, tracking the cells' distribution and effects.
Potential Biases
Potential bias due to the small number of patients and lack of control group.
Limitations
The study had a small sample size and most patients progressed on therapy.
Participant Demographics
Patients had advanced solid tumors unresponsive to other therapies.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website